No registrations found.
ID
Source
Brief title
Health condition
Inflammatory bowel disease,
Crohn's disease
Colitis Ulcerosa
Sponsors and support
Afdeling MDL en Klinische farmacologie
Intervention
Outcome measures
Primary outcome
The primary outcome measure is the correlation between fat mass, measured by an validated body composition monitor(BCM), and the IFX level. This will be measured prior to the IFX infusion. The IFX concentration will be measured and analysed in blood. Prior to de IFX infusion the trough level will be measured (according to regular health care). 30 minutes after the end of the infusion the top level will be measured.
Secondary outcome
Secondarily, the body composition(skinfold thickness, waist circumference, hand grip strength), BMI and body surface will be correlated to the IFX concentration. Furthermore, the disease activity, inflammation parameters and the amount of adverse effects will be measured en correlated to the fat mass.
Background summary
Background and problem statement:
Patients suffering from inflammatory bowel disease (IBD) are treated with anti-TNFalpha (TNFi) medication in 10-30% of the cases. In the current practice the dose of most of the TNFi medications are based on the weight of the patients, Infliximab (IFX) in particular. However, some studies show that this dose is not optimal. Therefore, other methods must be investigated.
Research question :
What is the relation between of body composition(body fat mass) and the IFX level, with the IFX dose based on the body weight, in an IBD population using IFX medication? Secondarily; Is the effectiveness of IFX related to the body composition in IBD patients starting with TNFi medication?
Setting of the research and subjects:
In this observational study patients receiving IFX infusion every 8 weeks and patients starting with IFX for the treatment of ulcerative colitis or Crohn’s disease will be included. The relation between body composition and IFX level will be measured in patients receiving IFX infusion every 8 weeks following a transversal study design. Furthermore, patients starting with IFX need to receive a loading dose of 3 gifts in order to reach a steady state. Therefore the IFX level will be measured after the third IFX infusion. In this patient group, the effect of IFX related to the body composition can be investigated.
Methods of data collection
Body composition will be measured with non-invasive methods; validated scale for fat mass, skinfold measure, squeezing force and waist circumference. To calculate BMI and body surface; length and bodyweight will be measured. Prior to the IFX infusion, the trough level will be determined, according to regular care. 30 minutes after the end of the infusion the top level will be determined. The inflammation parameters to evaluate the effectiveness are CRP in blood and calprotectin in feces and will be measured following regular healthcare.
Study objective
It is described in the literature that determining the dosage of IFX based on body weight does not seems ideal. Therefore other methods must be investigated in order to determine a more optimal dosage. The aim of this study is to investigate the relation between body composition, body surface and BMI and the IFX serum level. Besides, there will be investigated if body composition and BMI, and their possible pharmacokinetic consequences influence the effectiveness of the IFX medication in the IBD population.
We hypothesis that there is a stronger relation between body composition and IFX than there is with bodyweight and IFX.
Study design
T0: Prior to IFX infusion
- Body composition (fat mass by BCM, skinfold thickness, waist circumference, hand grip strength), height and weigth
- Inflammation parameters (CRP calprotectine)
- Trough level IFX
T1: 30 minutes after IFX infusion
- Top level IFX
T2: after IFX infusion
- Inflammation parameters (CRP calprotectine)
- Adverse effects
Intervention
Not applicable (observational study)
Inclusion criteria
Patiënt are eligible to participate in the study if all of the following criteria are met:
1. Patient, male or female, is aged above 18 years
2. Patient has an established diagnosis of ulcerative colitis or Crohn’s disease
3. Patients is being treated with, or start with the treatment IFX for a period of at least 12 weeks, or for the first
time during the study period.
4. Patiënt must be able to understand the patient information and the explanation of the investigator
5. Patient must be able to undergo the study measurements and understand the instructions of the investigator
6. Patient is informed about the intention and nature of the study including the possible risks and has signed the
informed consent before inclusion.
Exclusion criteria
Patients are not eligible if one or more of the following criteria are met:
1. Patient is mentally or physically not able to participate to the study, including severe mental illness.
2. Patient has had a change in the dosage of the IFX during the last 5 weeks.
3. Patients who is currently pregnant, breastfeeding, or is planning to become pregnant during the study period.
4. Patients suffering from severe comorbidities which can influence the body composition of the pharmacokinetics
of IFX;
a. Current malignancy or a malignancy in the recent history (<5 years), except cutaneous basal cell carcinoma
and cutaneous squamous cell carcinoma.
b. (history of) Liver/renal failure
c. Short Bowel Syndrome
d. Heart failure defined as; New York Heart Association (NYHA) Class III or IV
5. Patients participating in other studies, or participated I another study with an intervention in de last 4 months.
Design
Recruitment
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL6757 |
| NTR-old | NTR7626 |
| CCMO | NL66944.096.18 |
| OMON | NL-OMON46317 |